Webinar Invite STARTING IN 30 MIN: Debriefing 1Q26 Pharma Earnings - What the Quarter Told Us & What's Coming Next

研报英文原文证据摘录

Webinar Invite STARTING IN 30 MIN: Debriefing 1Q26 Pharma Earnings - What the Quarter Told Us & What's Coming Next

Biotechnology May 11, 2026

Seamus Fernandez

seamus.fernandez@guggenheimpartners.com Webinar Invite STARTING IN 30 MIN: Debriefing

617 859 4637 1Q26 Pharma Earnings - What the Quarter Told Us & Vamil Divan, M.D.

vamil.divan@guggenheimpartners.com What's Coming Next

212 823 6543

Daniel Krizay, Ph.D. Please join us for a discussion with Seamus Fernandez and Vamil Divan, M.D., daniel.krizay@guggenheimpartners.com

212 823 6561 facilitated by Healthcare Sales Specialist Whitney Wolfe. Seamus and Vamil will discuss

major takeaways and updates across their combined large cap biopharma coverage

Arseniy Shabashvili coming out of 1Q 2026 earnings, as well as their favorite ideas looking ahead to 2H 2026.

arseniy.shabashvili@guggenheimpartners.com The discussion will be moderated by our Healthcare Sales Specialist Whitney Wolfe, and 212 699 1971

we will also field any inbound questions from investors.

Edouard Mullarky, Ph.D.

edouard.mullarky@guggenheimpartners.com Potentially Impacted Companies: ABBV, AMGN, AZN-LON, BMY, GSK-LON, JNJ,

212 518 9579 LLY, MRK, NOVN-SWX, NOVO.B-CSE, PFE, SAN-PAR, and others

Evan Wang

evan.wang@guggenheimpartners.com Please register HERE or contact your Guggenheim Sales Representative

212 651 9756

Alana Lelo, Ph.D. Discussion Topics

alana.lelo@guggenheimpartners.com

212 518 9955 • What we learned from 1Q 2026 earnings

• Commercial and pipeline dynamics in obesity, immunology, oncology and other important

Colleen Garvey, Ph.D. markets

colleen.garvey@guggenheimpartners.com • Important clinical pipeline and other catalyst changes coming out of earnings 617 859 4664

• Pharma’s latest on M&A (e.g., deal stage and size) and appetite for deals